1. Pink Sheet

IPR Battles Could Become Easier For BioPharma Patent Owners

 
• By Brenda Sandburg

En banc Federal Circuit says patent owners do not have to prove patentability of amended claims in inter partes review proceedings; judges issue five opinions in fractured decision.

Court of Appeals for Federal Circuit Lafayette Park Across from White House Washington DC
The fate of many government policies is decided not at the White House, but across Lafayette Park at the US Court of Appeals for Federal Circuit.

Bipharma patent owners gained some ground in their battle against the inter partes review (IPR) process as the US Court of Appeals for the Federal Circuit issued an en banc ruling that patent owners do not have the burden of proving the patentability of amended claims in these proceedings.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

Switzerland Simplifies Imports Of Unauthorized Drugs To Tackle Drug Shortages

 
• By Eliza Slawther

Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.

EU ‘Can’t Expect Industry To Give Up Proprietary Insights’ Under Health Data & Clinical Trials Regulations

 
• By Eliza Slawther

Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.

How Tumult At US FDA Could Impact Merger and Acquisition Strategy

 
• By Joseph Haas and Nielsen Hobbs

With review and development uncertainly increasing, "it’s going to take longer for certain targets … to progress to a place where they’ve been derisked enough that big pharma is ready to write a big check," said Andrew Goodman of Paul Hastings.